{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-2S62N32E/7c2f52b9-5ea7-4d41-86db-737837a36d03/PDF","dcterms:extent":"1964 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-2S62N32E/e726fb67-2861-4aae-928f-02feab035b39/TEXT","dcterms:extent":"40 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-2S62N32E","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2022","dc:creator":["Jančič, Eva","Janež, Andrej","Janić, Miodrag","Jovanović, Marija","Lunder, Mojca"],"dc:contributor":"Lunder, Mojca","dc:format":[{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"letnik:73"},{"@xml:lang":"sl","#text":"str. 231-240"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:114653443","URN:URN:NBN:SI:doc-2S62N32E"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"agonisti receptorjev GLP-1"},{"@xml:lang":"sl","#text":"antidiabetično zdravljenje"},{"@xml:lang":"en","#text":"antihyperglycaemic treatment"},{"@xml:lang":"en","#text":"GLP-1 receptor agonists"},{"@xml:lang":"en","#text":"oral semaglutide"},{"@xml:lang":"sl","#text":"peroralni semaglutid"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Semaglutid - prvi peroralni agonist receptorjev GLP-1 za zdravljenje sladkorne bolezni tipa 2| Semaglutide - the first oral GLP-1 receptor agonist for the treatment of type 2 diabetes|"},"dc:description":{"@xml:lang":"sl","#text":"Optimal glycemic control and multifactorial treatment are important for type 2 diabetes control. Non-pharmacological treatment is the mainstay of antihyperglycemic treatment, but it usually merits timely escalation of pharmacological intervention. One of the barriers to pharmacological treatment with GLP-1 receptor agonists was injectable treatment due to their polypeptide composition. In 2019, the first and only oral GLP-1 receptor agonist – semaglutide, was introduced to clinical use. Due to structural modifications and technological processing of the tablet, the molecule is resistant to degradation in the acidic gastric envi- ronment and has a comparable effect as in the form of injectable treatment. Oral semaglutide was effective in improving glycemic control and redu- cing body weight, and proven for its cardiovascular safety. The present article describes the mechanism of action of GLP-1 receptor agonists, the development of oral semaglutide, dosing instructions and data from studies of its efficacy and safety"},"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-2S62N32E","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-2S62N32E"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-2S62N32E/7c2f52b9-5ea7-4d41-86db-737837a36d03/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-2S62N32E/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-2S62N32E"}}}}